CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 39 enrolled
Drug / intervention
pimavanserin tartrate (ACP-103)drug
Likely dose
pimavanserin tartrate (ACP-103) 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01518309
NCT01518309Phase 2Completed
CompareCT.gov

An Open-Label Safety Study of Pimavanserin in Parkinson's Disease Patients

ACADIA Pharmaceuticals Inc.·interventional·Posted Jan 26, 2012·Updated Nov 23, 2020

In Brief

A Phase 2 clinical trial evaluating pimavanserin tartrate (ACP-103) for Parkinson's Disease Psychosis. Completed, enrolled 39 participants across 1 site.

Detailed Summary

This is an open-label extension study to assess the long-term safety and tolerability of pimavanserin (ACP-103) in subjects with Parkinson's Disease Psychosis (PDP).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease Psychosis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 26, 2012
Enrollment StartNov 17, 2004
Primary CompletionMay 2, 2013
TodayJul 2, 2026
Enrollment to primary: 8.5 yearsPosted 14.4 years ago

Interventions

pimavanserin tartrate (ACP-103)drug

Tablets taken once daily by mouth at 20, 40, or 60 mg doses